Bruin Pharma

Bruin Biopharma is a preclinical-stage biotechnology company dedicated to developing small molecule inhibitors for oncology indications. The company's core technology focuses on targeting Ubiquitin-Specific Protease 7 (USP7), an enzyme that regulates the degradation of critical proteins involved in tumor suppression and immune response. By inhibiting USP7, Bruin Biopharma's lead compounds aim to stabilize p53 and other tumor suppressors to promote cancer cell death. The company was founded as a spin-off from the University of California, Los Angeles (UCLA), utilizing research from the labs of prominent medicinal chemists.